Patients’ characteristics of the ART long-term cohort patients at the time of ART initiation, stratified by enrolment in the previous research cohort
| Patients’ characteristics | Research cohort, n=345 (34.5%) | Clinic patients, n=655 (65.5%) | Overall, n=1000 | p Value |
| Sex, female, n (%) | 242 (70.1) | 377 (57.6) | 619 (61.9) | <0.001 |
| Age in years, median (IQR) | 35 (30–40) | 36 (31–41) | 36 (31–41) | 0.008 |
| WHO stages 3 and 4 | 310 (89.7) | 476 (72.9) | 786 (78.8) | <0.001 |
| BMI (kg/m2), median (IQR) | 20.3 (18.4–22.7) | 20.5 (18.8–22.7) | 20.3 (18.7–22.7) | 0.109 |
| Hb (g/dL), median (IQR) | 11.8 (10.5–13.0) | 11.4 (10.1–12.9) | 11.6 (10.3–12.9) | 0.026 |
| CD4 count (cells/µL), median (IQR) | 102 (30–168) | 66 (24–144) | 81 (26–155) | 0.004 |
| HIV RNA log10 (copies/mL), median (IQR) | 5.44 (5.08–5.74) | NA | 5.4 (5.08–5.74) | |
| ART regimen* | 0.010 | |||
| Nevirapine | 254 (73.6) | 548 (83.8) | 802 (80.3) | |
| Efavirenz | 91 (26.4) | 106 (16.2) | 197 (19.7) |
*Nevirapine based (nevirapine+stavudine+lavidune); efavirenz based (efavirenz+zidovudine+lamivudine).
All comparisons made using Pearson χ2 test and Wilcoxon rank sum test.
ART, antiretroviral treatment; BMI, body mass index; Hb, haemoglobin; NA, not applicable.